Differential impact of hormone receptor status on survival and recurrence for HER2 receptor-positive breast cancers treated with Trastuzumab.

Breast Cancer Res Treat · 2017 · PMC5487720 · PMID 28378298

Europe PMC DOI

hedged sentence

0.0750

closest p · 1.5× alpha

0.0750

boldest claim

The sentences

approached significancep = 0.075so close (0.05 < p ≤ 0.1)

HER2+(ER−) breast cancers did show decreases in all metastatic sites except for brain in Trast +ve patients; however, these reductions only approached significance in bone ( p = 0.075), lung ( p = 0.086) and liver ( p = 0.075).

also in 8,237 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.